At Shockwave, we’re committed to the creation of sound clinical evidence to support the adoption and long-term utilization of our technology. This includes a balance of high-quality Shockwave-sponsored and investigator-initiated research studies to advance the knowledge of our technology’s performance in daily practice.
While you can read more about our company-sponsored clinical trials on the website here, there hasn’t been a good resource for our customers to understand what investigator-initiated studies we’re also supporting…until now.
Read More
Topics:
Coronary Clinical Data,
Shockwave C2
Last month, we had the pleasure of being hosted by Prof. Holger Nef from Giessen, Germany, and Dr. Nikos Werner at his cath lab in Trier, Germany, for a day of cases followed by a live webinar with InCathLab.
Read More
Topics:
Coronary IVL,
Coronary Cases,
Shockwave C2
Recently, Dr. Stefan Harb partnered with Drs. Patrick Siegrist and Tim Schäufele to host the first ever IVL workshop in the DACH region at LKH Graz II Standort West in Graz, Austria. We asked Stefan to relay some of his key takeaways during the workshop and some of the more interesting discussions for the benefit of IVL users across the EU. We hope you enjoy his recap:
Read More
Topics:
Coronary IVL,
IVL Technology,
Coronary Cases,
Shockwave C2
The inaugural TopShock Symposium celebrating the one-year anniversary of coronary IVL at EuroPCR 2019 was a momentous occasion for everyone who participated, but none more so than for Dr. Alfonso Jurado-Román, the winner of the case competition.
Read More
Topics:
Coronary Cases,
Shockwave C2,
Coronary Conferences
The complete DISRUPT CAD II study findings have been published by the AHA’s journal, Circulation: Cardiovascular Interventions, and while it’s definitely worth the full read, we know that sometimes there just aren’t enough hours in the day. For a quick synopsis, we took the liberty to summarize some of the key data points into a visual-friendly infographic for you to review some of the study’s most important findings.
Read More
Topics:
Coronary Clinical Data,
Shockwave C2
For international customers currently using our coronary technology, we’re happy to report that coinciding with its presentation at TCT 2019 today, the DISRUPT CAD II study has also been simultaneously published by the AHA journal, Circulation: Cardiovascular Interventions.
Read More
Topics:
Coronary Clinical Data,
Shockwave C2
After being held in various cities over the recent years, TCT is back home where it belongs – back in the Bay, and joyfully, right in our backyard. We couldn’t be more excited about TCT this year. And no, it’s not just because those of us who live in the city are lucky enough to walk to work for a few beautiful September days.
Read More
Topics:
Coronary Cases,
Shockwave C2,
Coronary Conferences
Thanks to our UK distributor, Vascular Perspectives, for capturing a very compelling case from Dr. Richard Anderson, one of the longest standing commercial coronary IVL users in the in the UK at the University Hospital Wales. In the video he details out his treatment strategy for treating a heavily calcified RCA, LMS, LAD and LCX with a variety of calcium modification tools, including Shockwave IVL. Learn why he chooses Shockwave as his primary tool due to the patient’s moderate to severe left ventricular impairment. Hope you enjoy the case review!
Read More
Topics:
Coronary Cases,
Shockwave C2
Novelist, poet, playwright, and art collector Gertrude Stein is famous for the quote, “America is my country and Paris is my hometown.” Well, that’s exactly how we felt this spring with the warm reception IVL received at EuroPCR 2019.
Read More
Topics:
Coronary Cases,
Shockwave C2,
Coronary Conferences
